STAT

STAT+: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more

After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:
Source: Alex Hogan/STAT

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, so far, appears quite, , , and . And what about you? Given the ongoing heat on this side of the pond, this may be a good time to visit a beach or lake. Conversely, you could avoid people and remain indoors to binge watch something on the telly, assuming the air conditioning works. Or you could plan a summer getaway. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon…

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Access, Employer Coverage Of GLP-1 Drugs And More
Updates from the Pharmalittle newsletter campus: —FDA advised drugmakers to update Covid vaccines to target the KP.2 strain —Leadership from Done startup were arrested and charged with fraud —U.S. authorities…
STAT1 min read
STAT+: How A Tweet About A Gene Discovered Long Ago Led To A $190 Million Startup And, Maybe, Hope For Heart Disease
A 10-person startup called Marea has raised $190 million to help develop a drug to lower a type of cholesterol and a new way of attacking cardiovascular disease.

Related Books & Audiobooks